Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about
Identifieur interne : 001187 ( Main/Exploration ); précédent : 001186; suivant : 001188Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about
Auteurs : Mislav Radic [Croatie] ; Dusanka Martinovic Kaliterna [Croatie] ; Josipa Radic [Croatie]Source :
- Clinical Rheumatology [ 0770-3198 ] ; 2013-07-01.
English descriptors
Abstract
Abstract: The vasculature plays a crucial role in inflammation and atherosclerosis associated with the pathogenesis of rheumatoid arthritis. Vasculitis in rheumatoid arthritis is associated with longstanding disease, has an important impact on a patient’s quality of life and influences patient life expectancy. Seropositivity, specific human leukocyte antigen variations, antibodies to cyclic citrullinated peptides, and cigarette smoking are among the genetic and environmental predictors of rheumatoid vasculitis. Atherosclerosis is an early and common finding in rheumatoid arthritis and it correlates with disease duration, activity, and severity. Apart from conventional risk factors such as cigarette smoking, physical inactivity, obesity, arterial hypertension, dyslipidemia and diabetes mellitus, rheumatoid arthritis-related risk factors including disease duration, severity and activity, rheumatoid factor and antibodies to cyclic citrullinated peptides status, functional impairment, C-reactive protein, radiographic changes, presence of the shared epitope, and treatment modalities are all implicated in the development of accelerated atherosclerosis. Atherosclerosis is also considered an inflammatory disease; thus, it may share common pathogenic mechanisms with rheumatic diseases such as rheumatoid arthritis. Advances in treatment of rheumatoid arthritis with disease-modifying biologic and nonbiologic agents will probably continue to reduce the incidence of vasculitis. Since the goal of treatment for rheumatoid arthritis is to decrease inflammatory burden, successful treatment may theoretically reduce the risk of accelerated atherosclerosis.
Url:
DOI: 10.1007/s10067-013-2273-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000486
- to stream Istex, to step Curation: 000486
- to stream Istex, to step Checkpoint: 000239
- to stream Main, to step Merge: 001188
- to stream Main, to step Curation: 001187
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about</title><author><name sortKey="Radic, Mislav" sort="Radic, Mislav" uniqKey="Radic M" first="Mislav" last="Radic">Mislav Radic</name></author><author><name sortKey="Kaliterna, Dusanka Martinovic" sort="Kaliterna, Dusanka Martinovic" uniqKey="Kaliterna D" first="Dusanka Martinovic" last="Kaliterna">Dusanka Martinovic Kaliterna</name></author><author><name sortKey="Radic, Josipa" sort="Radic, Josipa" uniqKey="Radic J" first="Josipa" last="Radic">Josipa Radic</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DFD688BD719DA507464E682ADF5FCF122087A2B2</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s10067-013-2273-8</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-NR4NP9X5-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000486</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000486</idno><idno type="wicri:Area/Istex/Curation">000486</idno><idno type="wicri:Area/Istex/Checkpoint">000239</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000239</idno><idno type="wicri:doubleKey">0770-3198:2013:Radic M:overview:of:vasculitis</idno><idno type="wicri:Area/Main/Merge">001188</idno><idno type="wicri:Area/Main/Curation">001187</idno><idno type="wicri:Area/Main/Exploration">001187</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about</title><author><name sortKey="Radic, Mislav" sort="Radic, Mislav" uniqKey="Radic M" first="Mislav" last="Radic">Mislav Radic</name><affiliation wicri:level="1"><country xml:lang="fr">Croatie</country><wicri:regionArea>Division of Rheumatology and Clinical Immunology, University of Split School of Medicine, University Hospital Centre Split, Šižgorićeva 20/II, 21 000, Split</wicri:regionArea><wicri:noRegion>Split</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Kaliterna, Dusanka Martinovic" sort="Kaliterna, Dusanka Martinovic" uniqKey="Kaliterna D" first="Dusanka Martinovic" last="Kaliterna">Dusanka Martinovic Kaliterna</name><affiliation wicri:level="1"><country xml:lang="fr">Croatie</country><wicri:regionArea>Division of Rheumatology and Clinical Immunology, University of Split School of Medicine, University Hospital Centre Split, Šižgorićeva 20/II, 21 000, Split</wicri:regionArea><wicri:noRegion>Split</wicri:noRegion></affiliation></author><author><name sortKey="Radic, Josipa" sort="Radic, Josipa" uniqKey="Radic J" first="Josipa" last="Radic">Josipa Radic</name><affiliation wicri:level="1"><country xml:lang="fr">Croatie</country><wicri:regionArea>Division of Nephrology, University of Split School of Medicine, University Hospital Centre Split, Split</wicri:regionArea><wicri:noRegion>Split</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer London</publisher><pubPlace>London</pubPlace><date type="published" when="2013-07-01">2013-07-01</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="937">937</biblScope><biblScope unit="page" to="942">942</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atherosclerosis</term><term>Rheumatoid arthritis</term><term>Rheumatoid vasculitis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The vasculature plays a crucial role in inflammation and atherosclerosis associated with the pathogenesis of rheumatoid arthritis. Vasculitis in rheumatoid arthritis is associated with longstanding disease, has an important impact on a patient’s quality of life and influences patient life expectancy. Seropositivity, specific human leukocyte antigen variations, antibodies to cyclic citrullinated peptides, and cigarette smoking are among the genetic and environmental predictors of rheumatoid vasculitis. Atherosclerosis is an early and common finding in rheumatoid arthritis and it correlates with disease duration, activity, and severity. Apart from conventional risk factors such as cigarette smoking, physical inactivity, obesity, arterial hypertension, dyslipidemia and diabetes mellitus, rheumatoid arthritis-related risk factors including disease duration, severity and activity, rheumatoid factor and antibodies to cyclic citrullinated peptides status, functional impairment, C-reactive protein, radiographic changes, presence of the shared epitope, and treatment modalities are all implicated in the development of accelerated atherosclerosis. Atherosclerosis is also considered an inflammatory disease; thus, it may share common pathogenic mechanisms with rheumatic diseases such as rheumatoid arthritis. Advances in treatment of rheumatoid arthritis with disease-modifying biologic and nonbiologic agents will probably continue to reduce the incidence of vasculitis. Since the goal of treatment for rheumatoid arthritis is to decrease inflammatory burden, successful treatment may theoretically reduce the risk of accelerated atherosclerosis.</div></front></TEI><affiliations><list><country><li>Croatie</li></country></list><tree><country name="Croatie"><noRegion><name sortKey="Radic, Mislav" sort="Radic, Mislav" uniqKey="Radic M" first="Mislav" last="Radic">Mislav Radic</name></noRegion><name sortKey="Kaliterna, Dusanka Martinovic" sort="Kaliterna, Dusanka Martinovic" uniqKey="Kaliterna D" first="Dusanka Martinovic" last="Kaliterna">Dusanka Martinovic Kaliterna</name><name sortKey="Radic, Josipa" sort="Radic, Josipa" uniqKey="Radic J" first="Josipa" last="Radic">Josipa Radic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001187 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001187 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DFD688BD719DA507464E682ADF5FCF122087A2B2
|texte= Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about
}}
| This area was generated with Dilib version V0.6.33. |  |